59482
document
The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet and inflammatory biomarkers in patients with metabolic syndrome . In a randomized , double-blind , crossover study of 15 aspirin-naive patients ( mean age 48.8 ± 10.2 years ) with the metabolic syndrome , statin monotherapy ( simvastatin 40 mg daily ) was compared to combination therapy ( simvastatin 40 mg and ezetimibe 10 mg daily ) on biomarkers of inflammation and platelet activity . The addition of ezetimibe to simvastatin over a 4-week period was associated with reduced expression of CD141 ( thrombomodulin ; p = 0.02 ) , platelet endothelial cell adhesion molecule ( p < 0.0001 ) and CD51/61 ( vitronectin receptor ; p = 0.048 ) compared to statin monotherapy . Ezetimibe added to simvastatin improves several indices of platelet reactivity beyond statin monotherapy . However , the clinical relevance of these findings await results of the IMPROVE-IT trial ( Improved Reduction of Outcomes : Vytorin Efficacy International Trial ) .
59483
Intervention_Pharmacological
ezetimibe/simvastatin
59484
Intervention_Pharmacological
simvastatin monotherapy
59485
Intervention_Pharmacological
aspirin-naive
59486
Outcome_Physical
platelet
59487
Outcome_Physical
inflammatory biomarkers
59488
Participant_Condition
patients with metabolic syndrome .
59489
Participant_Sample-size
15 aspirin-naive patients
59490
Participant_Age
mean age 48.8 ± 10.2 years
59491
Participant_Condition
metabolic syndrome